Spatially activatable intracellular payload platform
Roche-selected targeting biology can determine where the payload goes. GenLumina adds an independent light-controlled layer determining where cytotoxic activity is activated.
A focused PoC can test whether these two control layers create a differentiated therapeutic architecture.
GenLumina is developing a proprietary light-activated intracellular oncology payload platform that separates molecular tumor targeting from spatial payload activation. Rather than asking Roche to adopt an existing GenLumina target, the proposed collaboration can start with an antibody, peptide or ligand selected around Roche or Genentech biology.
Aligned with two stated Roche partnering priorities.
Roche highlights ADCs within Oncology and Haematology, and targeted or intracellular delivery within Research Technologies. GenLumina's hypothesis is that light-controlled payload activation can add a second layer of selectivity to those targeted-delivery architectures.
Novel enabling modality
A controllable intracellular payload layer designed to complement partner-owned targeting biology.
Targeted delivery
Modular conjugation to antibodies, peptides and other targeting ligands for intracellular delivery.
Oncology & ADC relevance
Preclinical activity across breast and colorectal cancer models, with potential applicability to targeted conjugate architectures.
Independent spatial control
Molecular targeting determines delivery; local light provides a separate activation control intended to improve selectivity.
Two layers of precision.
One controllable payload.
Molecular targeting
A Roche- or Genentech-selected antibody, peptide or ligand directs the construct toward selected tumor biology.
Intracellular delivery
The GenLumina payload is delivered into and localizes within targeted cells.
Spatial activation
Local light activates the intracellular payload within the intended treatment volume.
Selective killing
The activated payload drives tumor-cell cytotoxicity within the illuminated field.
A second, independent layer of selectivity.
Molecular targeting controls delivery. GenLumina adds spatial control over payload activation, designed to confine cytotoxic activity to the illuminated treatment volume.
- In-vitro proof-of-concept in targeted and conjugated approaches
- Activity demonstrated in breast and colorectal cancer models
- Antibody- and peptide-targeted platform starting points
- Conjugation and stability with a Roche-/Genentech-selected antibody, peptide or ligand
- Cellular uptake and intracellular localization
- Controlled activation, tumor-cell killing, selectivity and therapeutic-window assessment
- Progression to in-vivo PoC if predefined criteria are met
Roche does not need to adopt an existing GenLumina target.
GL-001 and GL-002 are internal evidence programmes that demonstrate platform breadth across peptide- and antibody-based targeting. A Roche collaboration can instead start directly with Roche-/Genentech-selected targeting biology.
One focused feasibility question.
Can a Roche-/Genentech-selected tumor-targeting antibody, peptide or ligand be combined with the GenLumina payload to create a differentiated, spatially controllable therapeutic architecture?
Conjugation feasibility, construct quality, stability, cellular uptake and intracellular localization.
Controlled activation, tumor-cell killing, selectivity and therapeutic-window assessment.
Progress to in-vivo PoC when jointly predefined technical and biological criteria are met.
Validate first. Create the option to licence.
The immediate proposal is scientific feasibility. Commercial rights do not need to be granted before the biology has been tested. The parties can, however, define upfront how a successful PoC could create an agreed option to progress toward programme-specific licensing.
Roche targeting biology
Select one antibody, peptide or ligand around a relevant Roche or Genentech oncology programme.
Partner-specific PoC
Test conjugation, uptake, localization, activation, selectivity and tumor-cell killing against jointly agreed criteria.
Decide whether to advance
If predefined criteria are met, Roche can progress an agreed option toward broader development and commercial rights.
Programme-specific rights
Commercial rights can then be negotiated for a defined indication, programme and geographic territory while GenLumina retains ownership of the underlying platform.
The intended structure preserves GenLumina's ability to develop the core payload platform and work with additional partners while granting separately negotiated rights around a defined Roche programme.
Evaluate one Roche-selected targeting conjugate.
We propose a focused scientific discussion to select the targeting biology, define the PoC work package and agree the decision criteria that could create an option to advance a successful programme.